Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection

Trial Profile

A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Posaconazole (Primary) ; Posaconazole (Primary) ; Voriconazole; Voriconazole
  • Indications Aspergillosis; Fusariosis; Invasive bronchopulmonary aspergillosis; Zygomycosis
  • Focus Adverse reactions; Registrational
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 31 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 01 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Sep 2015 Protocol has been amended to reduce treatment period from '>42 days- up to 168 days' to 'up to 84 days'
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top